Filing Details

Accession Number:
0001209191-14-007978
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-02-06 15:53:40
Reporting Period:
2014-02-04
Filing Date:
2014-02-06
Accepted Time:
2014-02-06 15:53:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1305253 Celladon Corp CLDN Biological Products, (No Disgnostic Substances) (2836) 330971591
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
78003 Pfizer Inc 235 E. 42Nd Street
New York NY 10017
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-02-04 1,544,397 $0.00 1,544,397 No 4 C Direct
Common Stock Acquisiton 2014-02-04 23,145 $8.00 1,567,542 No 4 C Direct
Common Stock Acquisiton 2014-02-04 227,261 $8.00 1,794,803 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A-1 Convertible Preferred Stock Disposition 2014-02-04 19,289,531 $0.00 1,544,397 $0.00
Common Stock Convertible Promissory Notes Disposition 2014-02-04 23,145 $8.00 23,145 $8.00
Series A-1 Preferred Stock Series A-1 Preferred Warrants Disposition 2014-02-04 532,818 $0.00 532,818 $0.45
Common Stock Common Warrants Acquisiton 2014-02-04 42,659 $0.00 42,659 $5.61
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
0 2013-10-15 2018-10-15 No 4 C Direct
42,659 2013-10-15 2018-10-15 No 4 C Direct
Footnotes
  1. Every 12.49 shares of Series A-1 Preferred Stock automatically converted into 1 share of Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
  2. Automatic conversion, in connection with the Issuer's initial public offering, of convertible promissory notes, including principal and accrued interest.
  3. The shares were purchased at the Issuer's initial public offering.
  4. Represents the automatic conversion of Series A-1 Preferred Warrants into Common Stock Warrants on a 1-for-12.49 basis upon the closing of the Issuer's initial public offering.